The founder of Immunwork and T-E Meds, Dr. Tse-Wen Chang, shared the latest developments of the two companies on 11th January. He further announced Immunwork’s planned entry into the clinical stage in 2024. The two long-acting drugs, TE-8105 and TE-8214, are designed to target type-II diabetes, obesity, fatty liver diseases, and neuroendocrine tumors (NETs) as […]
Immunwork 2024 Investor Meeting – Results Presentation Read More »
Dr. Hsing-Mao Chu, CEO at T-E Meds, will be presenting at the prestigious World ADC conference in San Diego on October 16th (Monday) from 4:30 PM to 5:00 PM. He will unveil our groundbreaking joint technology of “Drug Bundles” and “Glycan Modification” in the applications of ADCs. He will also show how this innovative approach enables precise site-specific
Join our presentation at the World ADC San Diego 2023 Read More »
Reported link: https://www.ctee.com.tw/news/20230925700053-439901
Website link: https://news.gbimonthly.com/tw/article/show.php?num=61824&range=news
Website link: https://news.gbimonthly.com/tw/article/show.php?num=60662&utm_source=dable
Exciting News! Immunwork’s Latest Published Paper Offers Promising Solutions for Pancreatic Cancer Treatment, Diagnostics, and Applications in ADC and ARC! We are thrilled to announce the publication of our paper, “Site-specific Conjugation of 6 DOTA Chelators to a CA19-9-targeting scFv-Fc Antibody for Imaging and Therapy,” in the prestigious Journal of Medicinal Chemistry. Led by Dr.
Immunwork’s latest research result is published in J. Med. Chem. Read More »
Immunwork is thrilled to announce its participation in the upcoming BIO Asia-Taiwan conference. Join us on July 28th as Dr. Kun-Po Li delivers a captivating company presentation.
Immunwork will present at BIO Asia-Taiwan conference Read More »
Reported link: https://news.gbimonthly.com/tw/audiovisual/show.php?num=59755
T-E Meds has been selected as a finalist for the Start-up Stadium picking competition in the BIO international convention. T-E Meds stand out through its innovative “Multi-Arm Linker” technology platform. This technology can be utalized to design and create novel ADC/ARC drugs to improve the efficacy and safety. T-E Meds was also selected as an
BIO 2023 International Convention in Boston Read More »
Dr. Hsing-Mao Chu, VP of R&D at Immunwork is speaking at the 2nd Next-Generation Conjugates Summit in Boston next week. Dr. Chu will introduce our innovative antibody-radionuclide conjugate (ARC) technology platform and its application in pancreatic cancer diagnosis/treatment.Join us at this exciting conference!
Immunwork to present at the 2nd Next-Generation Conjugates Summit in Boston Read More »
